SCHEMBL14966705

SCHEMBL14966705

CC(C)(C)OC(=O)NCCN(Cc1cc(F)c(Br)cc1F)C(=O)OCc1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.41
IDO1 P14902 2/20 0.40
PARP1 P09874 1/20 0.38
CKS1B P61024 1/20 0.38
SKP1 P63208 1/20 0.38
SKP2 Q13309 1/20 0.38
AKT1 P31749 2/20 0.38
CCR6 P51684 1/20 0.38
PAX8 Q06710 1/20 0.38
MAPT P10636 1/20 0.38
PTGDR2 Q9Y5Y4 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.36
SIGMAR1 Q99720 1/20 0.36
AAK1 Q2M2I8 1/20 0.36
HDAC3 O15379 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC2 Q92769 1/20 0.36
NCOR2 Q9Y618 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14966158 0.84 SIGMAR1 (0.46) SYKIDO1CCR6PAX8MAPT
SCHEMBL14966170 0.81 L3MBTL1 (0.42) MAPTL3MBTL1
SCHEMBL14966414 0.81 PTGDR2 (0.41) CCR6PAX8PTGDR2
SCHEMBL16163327 0.81 SYK (0.43) SYKIDO1CKS1BSKP1SKP2
SCHEMBL15716592 0.80 SYK (0.55) SYKIDO1CKS1BSKP1SKP2
SCHEMBL25346745 0.78 CCR6 (0.52) SYKIDO1CKS1BSKP1SKP2
SCHEMBL25970217 0.78 SYK (0.53) SYKIDO1CKS1BSKP1SKP2
SCHEMBL2685379 0.78 SYK (0.50) SYKIDO1CKS1BSKP1SKP2
SCHEMBL14966587 0.78 AAK1 (0.41) IDO1PARP1CKS1BSKP1SKP2
SCHEMBL19795747 0.78 CCR6 (0.52) SYKIDO1CKS1BSKP1SKP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140309226-A1 PIPERIDINYL-SUBSTITUTED CYCLIC UREAS AS GPR119 MODULATORS ARRAY BIOPHARMA, INC. 2014-10-16 US disclosed
WO-2013074641-A1 PIPERIDINYL- SUBSTITUTED CYCLIC UREAS AS GPR119 MODULATORS ARRAY BIOPHARMA INC. (US) 2013-05-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140309226-A1 PIPERIDINYL-SUBSTITUTED CYCLIC UREAS AS GPR119 MODULATORS GPR119, UTS2R, GPR139 SYK 2451/4885IDO1 3688/4885PARP1 3838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.